Abstracts tagged "registry"

Abstract Number: 0501 • ACR Convergence 2024
How Fast Do JAK-inhibitors, TNF-inhibitors, Abatacept and IL-6 Inhibitors Act in Rheumatoid Arthritis? An International Collaboration of Registers of Rheumatoid Arthritis Patients (the “JAK-pot” Study)
Delphine Sophie Courvoisier¹, Yacine Mrad¹, Denis Mongin¹, Romain Aymon², Roberto Caporali³, Denis Choquette⁴, Catalin Codreanu⁵, Louis Coupal⁴, Doreen Huschek⁶, Kimme Hyrich⁷, Florenzo Iannone⁸, Tore K. Kvien⁹, Monika Mustak¹⁰, Dan Nordstrom¹¹, Nina Trokovic¹², Lucia Otero-Varela¹³, Karel Pavelka¹⁴, Manuel Enrique Pombo Suarez¹⁵, Sella A. Provan¹⁶, Ana Maria Rodrigues¹⁷, Ziga Rotar¹⁸, Prodromos Sidiropoulos¹⁹, Anja Strangfeld²⁰, Jakub Závada¹⁴, Sizheng Zhao²¹, Axel Finckh¹ and Kim Lauper¹, ¹Division of Rheumatology, Geneva University Hospitals, Geneva, Switzerland, ²Division of Rheumatology, Geneva University Hospitals, Collonges-sous-Salève, France, ³Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milan, Italy, ⁴Rhumadata™, Montreal, QC, Canada, ⁵University of Medicine and Pharmacy, Bucharest, Romania, ⁶German Rheumatism Research Center (DRFZ) Berlin, Berlin, Germany, ⁷Centre for Musculoskeletal Research, The University of Manchester, Manchester, United Kingdom, ⁸Rheumatology Unit- University of Bari "Aldo Moro", IT, Bari, Italy, ⁹Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway and University of Oslo (UiO), Institute of Clinical Medicine, Oslo, Norway, Oslo, Norway, ¹⁰Department of Internal Medicine II, Kaiser Franz Josef Hospital, Vienna, Austria, ¹¹Helsinki University Hospital, Helsinki, Finland, ¹²Department of Medicine and Rheumatology ROB-FIN, Helsinki University Hospital, Helsinki, Finland, ¹³Spanish Society of Rheumatology, Madrid, Spain, ¹⁴Institute of Rheumatology and Charles University, Praha, Czech Republic, ¹⁵Rheumatology Department, Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain, ¹⁶Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, ¹⁷Nova Medical School and Hospital dos Lusíadas, Lisbon, Portugal, ¹⁸University Medical Centre Ljubljana and University of Ljubljana, Ljubljana, Slovenia, ¹⁹University of Crete, Laboratory of Rheumatology, Autoimmunity and Inflammation. University Hospital, Rheumatology, Clinical Immunology. Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology, Heraklion, Greece, HERAKLIO, Greece, ²⁰German Rheumatism Research Center (DRFZ) Berlin and Charité University Medicine, Berlin, Germany, ²¹Centre for Musculoskeletal Research, The University of Manchester, Liverpool, United Kingdom
Background/Purpose: JAK-inhibitors (JAKi) have demonstrated a rapid onset of action; however, it is unclear how they compare to other targeted therapies in rheumatoid arthritis (RA).…
Abstract Number: 1404 • ACR Convergence 2024
Modeling Diversity in Systemic Lupus Erythematosus (SLE) Clinical Trials Using Real-world Data (RWD) Sources
Andrew Bevan¹ and Nora Carroll², ¹Integrated Project Solutions, PPD, part of Thermo Fisher Scientific, Cambridge, United Kingdom, ²Cardiovascular and General Medicine, Thermo Fisher Scientific, Athlone, Ireland
Background/Purpose: The FDA places emphasis on studying clinically relevant trial populations but does not address how these might be defined. SLE disproportionately affects women and…
Abstract Number: 2350 • ACR Convergence 2024
Do Smoking and Obesity Impact Secukinumab Treatment Outcomes? Real-world Data from 1,202 European Patients with Psoriatic Arthritis
Zohra Faizy Ahmadzay¹, Stylianos Georgiadis², Mikkel Ostergaard³, Bente Glintborg⁴, Signe Møller-Bisgaard⁵, Marion Pons⁶, Jette Heberg⁷, Sara Nysom Christiansen⁸, Simon Horskjær Rasmussen⁶, Anne Gitte Loft⁹, Isabel Castrejon¹⁰, Lucia Otero-Varela¹¹, Jakub Závada¹², Karel Pavelka¹², Jarno Rutanen¹³, Laura Kuusalo¹⁴, Michael Nissen¹⁵, Ziga Rotar¹⁶, Katja Perdan-Pikmajer¹⁶, Miguel Bernardes¹⁷, Bjorn Gudbjornsson¹⁸, Gerdur Gröndal¹⁸, Irene E. van der Horst-Bruinsma¹⁹, Karin Laas²⁰, Brigitte Michelsen²¹, Catalin Codreanu²², Daniela DiGuiseppe²³, Burkhard Moeller²⁴, Gökçe Kenar²⁵, Merete Hetland²⁶ and Lykke Oernbjerg², ¹Rigshospitalet Glostrup and Copenhagen University, Glostrup, Denmark, ²Rigshospitalet Glostrup, Glostrup, Hovedstaden, Denmark, ³Department of Clinical Medicine, University of Copenhagen and Center for Rheumatology, Copenhagen Center for Arthritis Research, Glostrup, Denmark, ⁴DANBIO, Rigshospitalet Glostrup and University of Copenhagen, Virum, Denmark, ⁵Rigshospitalet, Glostrup and Slagelse Hospital, Glostrup, Denmark, ⁶Rigshospitalet Glostrup, Glostrup, Denmark, ⁷Rigshospitalet Glostrup, København V, Denmark, ⁸Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark., Glostrup, Denmark, ⁹Aarhus University Hospital and Aarhus University, Horsens, Denmark, ¹⁰Hospital General Universitario Gregorio Marañón and Complutense University of Madrid, Madrid, Spain, ¹¹Spanish Society of Rheumatology, Madrid, Spain, ¹²Institute of Rheumatology and Charles University, Praha, Czech Republic, ¹³Tampere University Hospital, Tampere, Finland, ¹⁴University of Turku and Turku University Hospital, Turku, Finland, ¹⁵Geneva University Hospital, Geneva, Switzerland, ¹⁶University Medical Centre Ljubljana and University of Ljubljana, Ljubljana, Slovenia, ¹⁷São João Hospital Center and FMUP, Lisboa, Portugal, ¹⁸Landspitali University Hospital and University of Iceland, Reykjavik, Iceland, ¹⁹Department of Rheumatology, Radboud University Medical Centre, Nijmegen, Netherlands, ²⁰East-Tallinn Central Hospital, Tallinn, Estonia, ²¹Rigshospitalet, Glostrup and Diakonhjemmet Hospital and Sørlandet Hospital, Kristiansand, Norway, ²²University of Medicine and Pharmacy, Bucharest, Romania, ²³Karolinska Institutet, Stockholm, ²⁴Inselspital - University Hospital Bern, Bern, Switzerland, ²⁵Dokuz Eylul University School of Medicine, Izmir, Turkey, ²⁶Rigshospitalet Glostrup and University of Copenhagen, Glostrup, Denmark
Background/Purpose: Smoking and obesity are common in patients with psoriatic arthritis (PsA) and can lead to higher disease activity and poorer response to treatment with…
Abstract Number: 0517 • ACR Convergence 2024
Characterizing Infusion-Related Reactions in Patients with Rheumatoid Arthritis Treated with Biologic DMARDs: Observations from the KOBIO Registry
Ji-Won Kim¹, Ju-Yang Jung², Chang-Hee Suh³ and Hyoun-Ah Kim¹, ¹Ajou university school of medicine, Suwon, South Korea, ²Ajou University of medical school, Suwon, South Korea, ³Ajou University Hospital, Suwon, South Korea
Background/Purpose: The use of biologic disease-modifying antirheumatic drugs (bDMARDs) has revolutionized the management of rheumatoid arthritis (RA), despite their efficacy being occasionally limited by infusion-related…
Abstract Number: 1454 • ACR Convergence 2024
Treatment Patterns, Clinical Characteristics, and Patient-Reported Outcomes Among Patients with Axial Spondyloarthritis Treated in Real-World Rheumatology Practices in the US
Andrew Concoff¹, Riley Taiji², Linda Grennell-Merrick³, Jonathan Rodrigues³, Courtney McDermot⁴, Usha Madhukar Niak³, Raluca Ionescuittu⁵, Ariane Faucher², Francis Vekeman² and Tim Nguyen³, ¹United Rheumatology, a Specialty Networks Company, Cleveland, OH, ²StatLog Econometrics, Montreal, QC, Canada, ³Novartis, East Hanover, NJ, ⁴Novartis, Dublin, Ireland, ⁵StatLog Economitrics, Montreal, QC, Canada
Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic immune-mediated rheumatic disease with high comorbidity burden. Biologic disease-modifying anti-rheumatic drugs (bDMARDs) and patient-reported outcomes (PROs) are increasingly…
Abstract Number: 2365 • ACR Convergence 2024
Benefits of Achieving Early versus Late Clinical Response After Treatment with Biologic and Targeted Synthetic DMARDs Among Patients with PsA in the CorEvitas PsA/Spondyloarthritis Registry
Philip Mease¹, Xiaolan Ye², Christopher Saffore³, Thomas Iyile⁴, Priscila Magalhaes Reis Nakasato⁵, Taylor Blachley⁶, Paul R. Lakin⁶, Nicole Middaugh⁶ and Alexis Ogdie⁷, ¹Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, ²AbbVie Inc., Mettawa, IL, ³AbbVie Inc., waukegan, IL, ⁴AbbVie Inc., hyattsville, MD, ⁵AbbVie Inc., Randolph, NJ, ⁶CorEvitas, LLC, Waltham, MA, ⁷Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Treatment for psoriatic arthritis (PsA) often involves biologic and targeted synthetic DMARDs (b/tsDMARDs). Existing research suggests that starting treatment with b/tsDMARDs early may lead…
Abstract Number: 0581 • ACR Convergence 2024
Unmet Criteria for Achieving Minimal and Very Low Disease Activity Among Patients with Psoriatic Arthritis Initiating Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs in the CorEvitas PsA/SpA Registry
Alexis Ogdie¹, Chao Song², Nicole Middaugh³, Maya Marchese³, Melissa Eliot³, Robert Low² and Philip Mease⁴, ¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²UCB Pharma, Smyrna, GA, ³CorEvitas, LLC, Waltham, MA, ⁴Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA
Background/Purpose: Minimal disease activity (MDA) is associated with reduced radiographic progression and improved quality of life among patients (pts) with PsA.1 Clinical advances made MDA…
Abstract Number: 1460 • ACR Convergence 2024
Safety and Effectiveness of 97 Combinations of Targeted Therapies in Immune Mediated Inflammatory Diseases : Preliminary Data from the COMBATT Registry
Lou Kawka¹, Jacques-Eric Gottenberg², Jérôme Avouac³, OLIVIER BROCQ⁴, GILLES HAYEM⁵, Xavier Mariette⁶, Alain Meyer⁷, BENOIT FLACHAIRE⁸, OLIVIER FOGEL⁹, ARTHUR GANDIOLLE¹⁰, MANON LESTURGIE¹¹, JEAN-FRANCOIS KLEINMANN¹², Samira Ahmed Yahia¹³ and Thao Pham¹⁴, ¹Hôpital Universitaire de Strasbourg, Strasbourg, Alsace, France, ²Rheumatology Department, Strasbourg University Hospital,, Strasbourg, France, ³Rheumatology A Department, Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France, ⁴Service de Rhumatologie, centre hospitalier Princesse-Grâce, Monaco, Monaco, ⁵Groupe Hospitalier Paris Saint-Joseph, Paris, France, ⁶Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France, ⁷UR3072, Physiology Department, Rheumatology Department, University Hospital of Strasbourg, Strasbourg, France, ⁸Aix Marseille University, Marseille, France, ⁹AP-HP, Paris, France, ¹⁰Strasbourg University Hospital, Strasbourg, France, ¹¹Cochin hospital, Paris, France, ¹²Rheumatology department strasbourg, Strasbourg, France, ¹³Hôpital Universitaire de Strasbourg, Strasbourg, France, ¹⁴Assistance Publique-Hôpitaux de Marseille, Marseille, France
Background/Purpose: This study aimed to evaluate the clinical scenarios in which clinicians initiate cTT, as well as the safety and effectiveness of cTT in patients…
Abstract Number: 2412 • ACR Convergence 2024
Validation of Proposals for Definitions of Moderate and Severe Disease Activity in Systemic Lupus Erythematosus, Based on Data Gathered from the RELESSER-PROS Register Database
Irene Altabás-González¹, Íñigo Rúa-Figueroa², Coral Mouriño³, Ivonne Lourdes Mamani⁴, Karen Roberts⁵, Julia Martínez-Barrio⁶, María Galindo-Izquierdo⁷, Jaime Calvo-Alen⁸, MARIA CELIA ERAUSQUIN ARRUABARRENA⁹, Belen Serrano-Benavente⁶, Irene Carrión-Barberà¹⁰, Esther Uriarte-Isacelaya¹¹, Eva Tomero Muriel¹², Mercedes Freire González¹³, Ricardo Blanco-Alonso¹⁴, Eva Salgado-Pérez¹⁵, Paloma Vela-Casasempere¹⁶, Antonio Fernández-Nebro¹⁷, Alejandro Olive¹⁸, Clara Sanguesa¹⁹, Javier Narvaez-García²⁰, Raúl Menor Almagro²¹, José Rosas-Gómez de Salazar²², José Ángel Hernández Beriain²³, Francisco j. Manero-Ruiz²⁴, Elena Aurrecoechea²⁵, Carlos Montilla²⁶, gema Bonilla²⁷, Oihane Ibarguengoitia Barrena²⁸, Vicenç Torrente-Segarra²⁹, Ana Paula Cacheda³⁰, María García-Villanueva³¹, Clara Moriano³², Loreto Horcada³³, Nuria Lozano-rivas³⁴, Cristina Bohorquez³⁵ and José María Pego-Reigosa³⁶, and RELESSER-Group, ¹Complejo Hospitalario de Vigo, Vigo, Galicia, Spain, ²Department of Rheumatology, Hospital Universitario Doctor Negrín, Las Palmas de Gran Canaria, Las Palmas GC, Spain, ³Complejo Hospitalario Universitario de Vigo. IRIDIS (Investigation in Rheumatology and Immune-Mediated Diseases) Group, Galicia Sur Health Research Institute, Vigo, Spain, ⁴COMPLEJO HOSPITALARIO UNIVERSITARIO DE VIGO, Pontevedra, Spain, ⁵Sección Reumatología, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁶Hospital Gregorio Marañón, Madrid, Spain, ⁷Hospital 12 de Octubre, Madrid, Madrid, Spain, ⁸Hospital Universitario de Araba, Araba, Spain, ⁹Gob Canarias, Tenerife, Canarias, Spain, ¹⁰Hospital del Mar, Barcelona, Spain, ¹¹Hospital Univeritario de Donostia, San Sebastián, Spain, ¹²La Princesa Hospital, Madrid, Madrid, Spain, ¹³Complexo Hospitalario Universitario de A Coruña, La coruna, Galicia, Spain, ¹⁴Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain, ¹⁵Complejo Hospitalario de Orense, Ourense, Spain, ¹⁶Hospital General Universitario Alicante, Alicante, Spain, ¹⁷Department of Rheumatology, Hospital Universitario de Málaga, Málaga, Andalucia, Spain, ¹⁸Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain, ¹⁹Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ²⁰Hospital Universitario de Bellvitge, Barcelona, Spain, ²¹Department of Rheumatology, Hospital Jerez de la Frontera, Jerez de la Frontera, Spain, ²²Hospital Marina Baixa, PALMA DE MALLORCA, Comunidad Valenciana, Spain, ²³Rheumatology Department. Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran C, Spain, ²⁴H. Miguel Servet, Zaragoza, Spain, ²⁵Hospital de Sierrallana, Torrelavega, Spain, ²⁶Hospital Universitario de Salamanca, Salamanca, Castilla y Leon, Spain, ²⁷Hospital Clínico Universitario La Paz, Madrid, Spain, ²⁸Rheumatology Division, Galdakao-Usansolo University Hospital, Galdako, Spain, ²⁹Hospital Comarcal Alt Penedès-Garraf, Vilafranca, Spain, ³⁰Hospital Universitario Son Llàtzer, Mallorca, Spain, ³¹Hospital Ramón y Cajal, MADRID, Madrid, Spain, ³²Hospital León, LEON, Spain, ³³Hospital Complex of Navarra, Pamplona, Spain, ³⁴Virgen de la Arrixaca University Hospital, Murcia, Spain, ³⁵Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain, ³⁶Galicia Health Service (SERGAS), Vigo, Spain
Background/Purpose: In systemic lupus erythematosus (SLE), there is not a standardized and validated definition of states of moderate and severe SLE activity. The aim of…
Abstract Number: 0582 • ACR Convergence 2024
Achievement of Minimal and Very Low Disease Activity Among Patients with Psoriatic Arthritis Initiating Biologic or Targeted Synthetic Disease-Modifying Antirheumatic Drugs in the CorEvitas PsA/SpA Registry
Alexis Ogdie¹, Chao Song², Nicole Middaugh³, Maya Marchese³, Melissa Eliot³, Robert Low² and Philip Mease⁴, ¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²UCB Pharma, Smyrna, GA, ³CorEvitas, LLC, Waltham, MA, ⁴Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA
Background/Purpose: Minimal disease activity (MDA) is associated with clinically meaningful improvements in disease activity and patient (pt)-reported outcomes among pts with PsA.1 However, it is…
Abstract Number: 1671 • ACR Convergence 2024
Are Patient-reported Outcomes for Dactylitis, Uveitis, Psoriatic Skin and Nail Disease Valid in Patients with Psoriatic Arthritis?
Louise Nielung¹, Merete Hetland², Lone Skov³, Hans Albert Frandsen⁴, Lene Dreyer⁵ and Bente Glintborg⁶, ¹Rigshospitalet Glostrup and University of Copenhagen, Glostrup, Denmark, ²DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopedics, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark, Glostrup, Denmark, ³Department of Dermatology and Allergy, Copenhagen University Hospital - Herlev and Gentofte, Gentofte, Denmark, ⁴Patient Partner, Frederiksberg, Denmark, ⁵Department of Rheumatology, Aalborg UnIversity Hospital, København, Denmark, ⁶DANBIO, Rigshospitalet Glostrup and University of Copenhagen, Virum, Denmark
Background/Purpose: In routine care, Danish patients with psoriatic arthritis (PsA) are monitored in DANBIO, a nationwide clinical registry1. Patients enter patient-reported outcomes (PROs) online before…
Abstract Number: 2618 • ACR Convergence 2024
Population Health Management for Juvenile Idiopathic Arthritis in the Pediatric Rheumatology Care and Outcomes Improvement Network
Julia Harris¹, Catherine Bingham², Sheetal Vora³, Cagri Yildirim-Toruner⁴, Kerry Ferraro⁵, Erik Friedrichsen⁶, Danielle Bullock⁷, Jon Burnham⁸, Tzielan Lee⁹, Daniel Lovell¹⁰, Ted Wimmel¹¹, Delores Mincarelli¹¹, Mayur Patil¹², Magen Phillips¹¹ and Esi Morgan¹³, ¹Children's Mercy Kansas City, Overland Park, KS, ²Penn State Children’s Hospital, Hershey, ³Atrium Health Levine Children's Hospital, Charlotte, NC, ⁴Baylor College of Medicine/ Texas Children's Hospital, Houston, TX, ⁵JIA parent and CHOP volunteer, Lower Gwynedd, PA, ⁶Seattle Children's Hospital, Seattle, ⁷M Health Fairview Masonic Children’s Hospital, Minneapolis, ⁸Children's Hospital of Philadelphia, Philadelphia, PA, ⁹Stanford University School of Medicine, Palo Alto, CA, ¹⁰Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹¹Hive Networks, Newport, ¹²VSquare Infotech Inc, Edison, NJ, ¹³Seattle Children's Hospital, Seattle, WA
Background/Purpose: The Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN) is a learning health network with a vision that children with rheumatic disease will have…
Abstract Number: 0603 • ACR Convergence 2024
Superior Effectiveness and Comparable Drug Retention of Anti-TNF Therapy versus Anti-IL-17A in Ankylosing Spondylitis After First Anti-TNF Failure: A Propensity Score-Matched Analysis from the Czech ATTRA Registry
Jakub Závada¹, Jana Baranová², Karel Pavelka¹, Jiří Vencovský³, Pavel Horak⁴, Kateřina Kusalová² and Ladislav Šenolt³, and collaborators of the ATTRA registry, ¹Institute of Rheumatology and Charles University, Praha, Czech Republic, ²Institute of Biostatistics and Analyses, Ltd., Brno, Czech Republic, ³Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁴3rd Department of Internal Medicine - Nephrology, Rheumatology and Endocrinology, University Hospital Olomouc & Palacky University Olomouc, Faculty of Medicine and Dentistry, Olomouc, Olomoucky kraj, Czech Republic
Background/Purpose: This study aims to compare the drug survival, effectiveness, and safety of anti-IL-17A and anti-TNF drugs in patients with Ankylosing Spondylitis (AS) following the…
Abstract Number: 1869 • ACR Convergence 2024
Analysis of Short-Term Side Effects Following COVID-19 Vaccination in Pregnancies Complicated by Autoimmune Inflammatory Rheumatic Diseases
Shunya Kaneshita¹, Christina Chambers², Diana Johnson¹, Arthur Kavanaugh¹, Richard Garfein¹ and Gretchen Bandoli¹, ¹University of California San Diego, La Jolla, CA, ²University of California, San Diego, La Jolla, CA
Background/Purpose: Pregnant women are particularly at risk of severe Coronavirus disease 2019 (COVID-19) infection, which is why the Centers for Disease Control and Prevention (CDC)…
Abstract Number: 2621 • ACR Convergence 2024
Trends in Disease Activity in Rheumatoid Arthritis over 2009-2023 Utilizing DAS28-CRP Inferred from Electronic Health Records
David Cheng¹, Vidul Panickan², Andrew Cagan³, Gregory McDermott⁴, Mary Jeffway³, Ying Qi⁵, Feng Liu³, Michael Weinblatt⁶, Nancy Shadick⁵, Tianxi Cai⁷ and Katherine Liao³, ¹Massachusetts General Hospital, Boston, MA, ²Harvard Medical School, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women’s Hospital, Brookline, MA, ⁵Brigham and Women’s Hospital, Boston, MA, ⁶Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, ⁷Harvard T.H. Chan School of Public Health, Boston, MA
Background/Purpose: Systematic measurement and documentation of disease activity in RA patients is key for monitoring quality of care and is an important outcome and predictor…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].